UPLOAD Filing
Vor Biopharma Inc.
Date: Jan. 30, 2026 · CIK: 0001817229 · Accession: 0000000000-26-001167
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293052
Letter
January 30, 2026 Jean-Paul Kress, M.D. President, Chief Executive Officer and Chairman of the Board Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116 Re:Vor Biopharma Inc. Registration Statement on Form S-3 Filed January 29, 2026 File No. 333-293052 Dear Jean-Paul Kress M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Div Gupta, Esq.
Show Raw Text
January 30, 2026
Jean-Paul Kress, M.D.
President, Chief Executive Officer and Chairman of the Board
Vor Biopharma Inc.
500 Boylston Street, Suite 1350
Boston, MA 02116
Re:Vor Biopharma Inc.
Registration Statement on Form S-3
Filed January 29, 2026
File No. 333-293052
Dear Jean-Paul Kress M.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Div Gupta, Esq.